NOUVEAU COMPOSÉ AYANT LA CAPACITÉ À INHIBER L'ENZYME 11B-HSD1 OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, PROCÉDÉ DE PRODUCTION ASSOCIÉ, ET COMPOSITION PHARMACEUTIQUE CONTENANT CELUI-CI EN TANT QUE PRINCIPE ACTIF
BAMICHEM CO., LTD;Ahn-Gook Pharmaceutical Co., Ltd.;Incheon University Industry Academic Cooperation Foundation
发明人:
申请号：
EP13806654.3
公开号：
EP2865664B1
申请日:
2013.06.04
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11²-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11²-HSD1 (11²-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11²-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.
